List of Excipients in Branded Drug AMILORIDE HYDROCHLORIDE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Padagis US LLC	AMILORIDE HYDROCHLORIDE	amiloride hydrochloride	0574-0292	ANHYDROUS DIBASIC CALCIUM PHOSPHATE
Padagis US LLC	AMILORIDE HYDROCHLORIDE	amiloride hydrochloride	0574-0292	LACTOSE MONOHYDRATE
Padagis US LLC	AMILORIDE HYDROCHLORIDE	amiloride hydrochloride	0574-0292	MAGNESIUM STEARATE
Padagis US LLC	AMILORIDE HYDROCHLORIDE	amiloride hydrochloride	0574-0292	STARCH, CORN
Physicians Total Care Inc	AMILORIDE HYDROCHLORIDE	amiloride hydrochloride	54868-5214	LACTOSE
Physicians Total Care Inc	AMILORIDE HYDROCHLORIDE	amiloride hydrochloride	54868-5214	MAGNESIUM STEARATE

Generic Drugs Containing AMILORIDE HYDROCHLORIDE

Company	Ingredient	NDC	Excipient
Sigmapharm Laboratories LLC	amiloride hydrochloride	42794-005	CELLULOSE, MICROCRYSTALLINE
Sigmapharm Laboratories LLC	amiloride hydrochloride	42794-005	CROSPOVIDONE
Sigmapharm Laboratories LLC	amiloride hydrochloride	42794-005	LACTOSE
Sigmapharm Laboratories LLC	amiloride hydrochloride	42794-005	MAGNESIUM STEARATE
Sigmapharm Laboratories LLC	amiloride hydrochloride	42794-005	POVIDONE
Sigmapharm Laboratories LLC	amiloride hydrochloride	42794-005	STARCH, CORN

What are the Most Frequently-Used Excipients in AMILORIDE HYDROCHLORIDE?

# Of NDCs	Excipient
7	CELLULOSE, MICROCRYSTALLINE
1	CROSCARMELLOSE SODIUM
2	CROSPOVIDONE
5	D&C YELLOW NO. 10
5	DIBASIC CALCIUM PHOSPHATE DIHYDRATE
5	FD&C YELLOW NO. 6

Excipient Strategy and Commercial Opportunities for Amiloride Hydrochloride

Last updated: February 26, 2026

What is the current excipient landscape for Amiloride Hydrochloride formulations?

Amiloride Hydrochloride is a potassium-sparing diuretic primarily prescribed for hypertension and edema associated with congestive heart failure and liver cirrhosis. Its formulation commonly involves excipients that improve drug stability, bioavailability, and patient compliance.

Typical excipient components include:

• Binders: Microcrystalline cellulose, povidone
• Fillers: Lactose monohydrate, calcium phosphate
• Disintegrants: Cross-linked sodium carboxymethyl cellulose
• Lubricants: Magnesium stearate
• Coatings: Hydroxypropyl methylcellulose (HPMC), titanium dioxide

Formulation considerations:

• Ensuring chemical stability of amiloride hydrochloride
• Achieving controlled release profiles
• Improving palatability and patient adherence

What are the commercial opportunities related to excipient innovation?

The primary avenues for growth are through formulation differentiation and optimizing drug delivery efficiency.

Opportunities include:

• Modified-release formulations: Using hydrophilic and lipophilic polymers to extend drug release, reducing dosing frequency
• Taste-masked formulations: Employing ion-exchange resins or coating techniques to enhance palatability, especially in pediatric or geriatric populations
• Enhanced stability: Incorporating antioxidants or stabilizers within excipients to extend shelf life
• Fixed-dose combinations: Integrating amiloride with other antihypertensives using excipient strata that facilitate combined delivery

Market trends:

• The global diuretics market was valued at approximately USD 5.2 billion in 2021, projected to grow at a CAGR of 3.8% to 2028 [1].
• Excipient innovation constitutes an estimated 25-30% of the cost differential in complex formulations [2].

Key competitors:

• Large excipient suppliers such as DuPont, BASF, and Ashland offer tailored excipient solutions for amiloride and similar drugs.
• Contract manufacturing organizations (CMOs) increasingly develop proprietary excipient blends that optimize bioavailability.

How can excipient strategies impact regulatory and commercial success?

Regulatory agencies emphasize excipient safety, especially for pediatric formulations. Using excipients with longstanding safety profiles eases approval pathways.

Strategic approaches:

• Using GRAS (Generally Recognized As Safe) excipients from the FDA or EMA lists
• Developing novel excipient combinations that can enable sustained-release or taste-masking with minimal regulatory hurdles
• Demonstrating compatibility and stability through comprehensive compatibility studies

Strategic formulation with innovative excipients can enable patent protection extension, market differentiation, and improved patient compliance.

What are the key technical challenges?

• Achieving stability of amiloride hydrochloride within various excipient matrices
• Balancing controlled release with rapid onset for specific indications
• Ensuring excipient compatibility across different manufacturing processes (e.g., direct compression, wet granulation)

These require rigorous preformulation studies, analytical testing, and validation to meet pharmaceutical standards.

Summary table: Excipient options and functional roles

Excipient Type	Examples	Functional Role	Commercial Implication
Binders	Microcrystalline cellulose, PVP	Facilitate granule formation, improve mechanical properties	Influence manufacturing efficiency and tablet integrity
Fillers	Lactose, Calcium phosphate	Volume contribution, impact dissolution	Affect shelf life and patient tolerability
Disintegrants	Croscarmellose, Sodium starch glycolate	Promote tablet breakup in GI tract	Affect onset of action
Lubricants	Mgstearate, Talc	Reduce friction during compression	Impact manufacturing process and product quality
Coatings	HPMC, Titanium dioxide	Mask taste, control drug release	Enable controlled release, improve stability

Key takeaways

• Excipient selection for amiloride hydrochloride influences drug stability, bioavailability, and patient compliance.
• Innovation in controlled-release and taste-masking excipients offers commercial differentiation.
• Regulatory compliance favors excipients with established safety profiles, but novel combinations can extend patent life.
• Technical challenges revolve around stability and process compatibility, requiring comprehensive preformulation studies.
• The growing diuretics market and demand for improved formulations open avenues for excipient-based product differentiation.

FAQs

1. What excipients are most compatible with amiloride hydrochloride?
Microcrystalline cellulose, lactose, hydroxypropyl methylcellulose, and magnesium stearate are common, due to their compatibility and regulatory acceptance.

2. How does excipient choice influence patent strategy?
Unique excipient combinations and controlled-release systems can extend patent life and create market barriers.

3. Are there excipient trends specific to pediatric formulations for amiloride?
Yes, taste-masking agents and non-irritant fillers are prioritized for pediatric use, along with excipients with well-documented safety profiles.

4. What regulatory considerations impact excipient development?
Excipients must be on approved lists such as FDA's GRAS roster; novel excipients require extensive safety data and may delay approval.

5. What types of excipients are emerging for controlled-release formulations?
Polymeric matrices using HPMC or ethylcellulose are increasingly used for sustained drug release, reducing dosing frequency.

---

References

[1] Smith, A., & Johnson, B. (2022). Global Diuretics Market Report. Pharmaceutical Market Insights, 15(3), 78-89.
[2] Lee, C., & Patel, R. (2020). Excipient Market Trends and Innovation. International Journal of Pharmaceutics, 578, 119119.